In light of recent reports alleging overuse of atherectomy devices, the authors revisit the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
In light of recent reports alleging overuse of atherectomy devices, the authors revisit the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
Read Dr. Walker's commentary on the case series by Dr. Barath and colleagues, "Techniques of Mesenteric Artery Recanalization for Chronic Mesenteric Ischemia.”
Read Dr. Walker's commentary on the case series by Dr. Barath and colleagues, "Techniques of Mesenteric Artery Recanalization for Chronic Mesenteric Ischemia.”
Dr. Walker comments on “Acute Limb Ischemia as a Complication of COVID-19.” He discusses the authors' findings and addresses unanswered questions that remain about COVID-19 and cardiovascular complications.
Dr. Walker comments on “Acute Limb Ischemia as a Complication of COVID-19.” He discusses the authors' findings and addresses unanswered questions that remain about COVID-19 and cardiovascular complications.
Dr. S. Jay Mathews provides a guest editorial to discuss a unique case of ClotTriever (Inari Medical) thrombectomy within a femoralfemoral venous bypass.
Dr. S. Jay Mathews provides a guest editorial to discuss a unique case of ClotTriever (Inari Medical) thrombectomy within a femoralfemoral venous bypass.
Dr. Walker continues his discussion of the BEST-CLI randomized control trial comparing surgery-first with or without an adequate venous conduit vs endovascular-first treatment in patients with CLTI.
Dr. Walker continues his discussion of the BEST-CLI randomized control trial comparing surgery-first with or without an adequate venous conduit vs endovascular-first treatment in patients with CLTI.
Drs. Finn and Walker discuss the results of the long-awaited BEST-CLI randomized control trial, which was presented at the American Heart Association’s 2022 Scientific Sessions in November.
Drs. Finn and Walker discuss the results of the long-awaited BEST-CLI randomized control trial, which was presented at the American Heart Association’s 2022 Scientific Sessions in November.
Hechingen, November 20th, 2024. With two certificates granted by TÜV, Bentley achieved another break-through in extending indications for its stents in complex aortic interventions. Thanks to one certificate, the Bentley BeGraft stent now is...
Hechingen, November 20th, 2024. With two certificates granted by TÜV, Bentley achieved another break-through in extending indications for its stents in complex aortic interventions. Thanks to one certificate, the Bentley BeGraft stent now is...
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD)
Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD)
Cardiovascular...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System
LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System
LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness
Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness
Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...